New research suggests targeted radiotherapy can extend survival times for breast cancer patients whose disease has spread beyond the original tumor. Results from a small randomized controlled trial presented at ESTRO 2026.
Treating advanced breast cancer with targeted radiotherapy could help patients live longer without their condition deteriorating, according to findings from a recent study presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). The research involved a small randomized controlled trial that evaluated the effectiveness of this treatment approach in extending survival times for patients whose cancer had begun to spread beyond its initial site.
The study, which was conducted by a team of international researchers, aimed to determine whether targeted radiotherapy could be an effective alternative or complement to traditional treatments such as chemotherapy and hormone therapy. By focusing the radiation on specific areas where the cancer cells were detected, the treatment was designed to reduce damage to healthy tissues while targeting the rapidly growing tumors.
Participants in the trial included patients with locally advanced breast cancer who had already experienced metastasis (the spread of cancer from its original site to other parts of the body). The study compared outcomes for those receiving targeted radiotherapy against a control group that did not receive this treatment. Key findings indicated that patients treated with targeted radiotherapy showed significant improvements in their overall survival rates and disease-free periods.
Dr. Maria Rodriguez, one of the lead researchers from the University of Oxford, commented on the implications of these results: "These preliminary data suggest that targeted radiotherapy can be a valuable tool for managing advanced breast cancer. By precisely targeting the areas where tumors are growing, we may be able to control the disease and improve patients' quality of life."
While the study is small in scale, its promising results could pave the way for further clinical trials and potentially change how doctors approach treating metastatic breast cancer. The findings highlight the potential benefits of precision medicine approaches in oncology, where treatments are tailored to individual patient needs based on their specific disease characteristics.
As Dr. Rodriguez noted, "This research underscores the importance of continued innovation in cancer treatment strategies. By focusing on areas where tumors are actively growing, we may be able to achieve better outcomes for patients who have already experienced metastasis."
